|
|
 |
|
Viewing report
|
|
|
|
Brief Report: GM-CSF Antibodies
La Merie, Jan 2008, Pages: 16
Product description The present Brief Report about molecules targeting granulocyte-macrophage colony-stimulating factor (GM-CSF) and its receptor or M-CSF or G-CSF and its receptor provides a competitor analysis of these anti-inflammatory antibodies. R&D projects of antibodies targeting GM-CSF/R, M-CSF or G-CSF/R to treat rheumatoid arthritis and other inflammatory diseases such as asthma, COPD, multiple sclerosis and psoriasis are discussed as of January 2008. A total of three different molecules are already in early clinical development and three others to follow within one year. After the establishment of anti-TNF therapies as a medically and economically successful therapy, interest in new targets for treatment of inflammation has shifted to other cytokines such as G/M-CSF/R.
The brief report with 16 pages describes the background of the target and the scientific rationale to develop molecules targeting G/M-CSF/R. The target markets for antibodies to G&M-CSF/R are discussed. The status of clinical and preclinical R&D is described and critically assessed. Individual profiles of the antibodies already in clinical development and to reach clinical development within one year are presented in an executive summary with references. The Brief Report also includes a summary list of the target pipeline with other research projects.
The Target Pipeline Summary presents a list in a tabular format providing information on:
Drug Codes, Target / Mechanism of Action, Class of Compound, Therapeutic Area, Company, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information.
Customers who bought this item also bought
Brief Report: Interleukin-13 (IL-13) Antibodies
Competitor Analysis: G-CSF & GM-CSF
U.S. CSF Management and Interventional Neuroradiology Markets
Monoclonal Antibodies Report: 2008 Update
Therapeutic Monoclonal Antibodies Markets
Brief Report: Interleukin-12 (IL-12) and IL-23 Antagonists
Brief Report: CD40 and CD40L (CD154) Agonists and Antagonists
Brief Report: Syk Kinase Inhibitors
Monoclonal Antibodies 2007: Competitive Landscape & Pipeline Insight
Competitor Analysis: CD20 Antibodies
Brief Report: Death Receptors TRAIL-R1/2
Molecules and Medicine
|
|
|
|
